Melanoma central nervous system metastases: current approaches, challenges, and opportunities.
Melanoma central nervous system metastases are increasing, and the challenges presented by this patient population remain complex. In December 2015, the Melanoma Research Foundation and the Wistar Institute hosted the First Summit on Melanoma Central Nervous System (CNS) Metastases in Philadelphia, Pennsylvania. Here, we provide a review of the current status of the field of melanoma brain metastasis research; identify key challenges and opportunities for improving the outcomes in patients with melanoma brain metastases; and set a framework to optimize future research in this critical area.
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Justine V
JV
Cohen
Department of Melanoma, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hussain
H
Tawbi
Department of Medical Oncology & Therapeutics Research, City of Hope Cancer Center, Duarte, CA, USA.
Kim A
KA
Margolin
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Ravi
R
Amravadi
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Marcus
M
Bosenberg
Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
Priscilla K
PK
Brastianos
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Veronica L
VL
Chiang
Division of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA.
John
J
de Groot
Department of Melanoma, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabella C
IC
Glitza
Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
Meenhard
M
Herlyn
Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
Sheri L
SL
Holmen
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Lucia B
LB
Jilaveanu
Department of Neurology & Herbert Irving Comprehensive, Cancer Center, Columbia University Medical Center, New York, NY, USA.
Andrew
A
Lassman
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stergios
S
Moschos
Department of Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.
Michael A
MA
Postow
Division of Neuro-Oncology, Department of Neurology, Stanford University, Stanford, CA, USA.
Reena
R
Thomas
Department of Radiology, New York-Presbyterian Hospital - Weill Cornell Medicine, New York, NY, USA.
John A
JA
Tsiouris
Department of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick
P
Wen
Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.
Richard M
RM
White
Melanoma Research Foundation, Washington, DC, USA.
Timothy
T
Turnham
Department of Melanoma, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A
MA
Davies
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Harriet M
HM
Kluger
D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy; D006801:Humans; D008545:Melanoma / Q000473:pathology* / Q000628:therapy
brain metastasis; clinical trials; experimental models; leptomeningeal disease; tumor microenvironment